A report demonstrates that the Incidence rates for malignant brain and other central nervous system tumors declined by 0.8% annually during 2008 through 2017 in the United States for all ages combined.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
